UK MARKET TALK ROUNDUP: BROKERS COMMENTS
15th Jul 2010 07:24
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0624 GMT [Dow Jones] The debate on GlaxoSmithKline's (GSK.LN) Avandia medicine will likely continue, despite the FDA Advisory
Read moreGlaxoSmithKline To Record A Legal Chg For 2Q Of GBP1.57B
15th Jul 2010 07:09
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a pharmaceutical and healthcare company, said Thursday it expects to record a legal charge for the second quarter of 2010 of GBP1.57 billion, equating to an after tax cost of GBP1.35 billion. MAIN FACTS: -The charge includes settlements, agre
Read moreGlaxo takes £1.6bn legal charge for Q2
15th Jul 2010 07:05
Drugs firm GlaxoSmithKline expects to record a legal charge for the second quarter of 2010 of £1.57bn. The legal charge settlements include an investigation by the US Government into the company's former manufacturing site at Cidra, Puerto Rico; product liability and anti-trust litigation relating
Read moreThursday newspaper round-up: BP, Fairfield Energy, Glaxo
15th Jul 2010 06:24
BP is facing a ban on getting any new offshore licences to produce oil and gas in the US for a number of years. A house committee has passed a bill stopping any company from getting permission to drill for seven years if it has caused more than 10 deaths during operations, while contravening health
Read moreMARKET TALK: GSK Pharma +0.9%; Ignores Drug Trial Suspension
15th Jul 2010 04:56
0356 GMT [Dow Jones] GlaxoSmithKline Pharmaceuticals (500660.BY) +0.9% at INR2,100.00 despite parent GlaxoSmithKline PLC (GSK.LN) suspending testing of diabetes drug Avandia at Indian sites participating in global clinical trial. GSK PLC suspended trials after Indian government requested hold due to
Read morePRESS RELEASE: GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia® (rosiglitazone)
14th Jul 2010 22:54
PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the
Read moreUPDATE: FDA Panel Recommends Keeping Glaxo's Avandia On US Market
14th Jul 2010 22:54
(Updates with Glaxo comments and information on India trial suspension starting in 10th paragraph.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A U.S. Food and Drug Administration panel voted Wednesday to recommend that GlaxoSmithKline PLC's (GSK) diabetes d
Read moreUPDATE: FDA Panel Recommends Keeping Glaxo's Avandia On US Market
14th Jul 2010 22:05
(Updates with details on the vote, panel member comments, background, starting in second paragraph; adds closing stock price) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A U.S. Food and Drug Administration panel voted Wednesday to recommend that GlaxoSmithKl
Read moreGlaxoSmithKline Suspends Avandia Trial In India
14th Jul 2010 21:59
By Peter Loftus Of DOW JONES NEWSWIRES GlaxoSmithKline PLC (GSK, GSK.LN) has suspended testing of its embattled diabetes drug Avandia at Indian sites participating in a global clinical trial, after the Indian government requested a hold due to recent studies raising safety concerns. The
Read moreFDA Panel Recommends Keeping Glaxo's Avandia On US Market
14th Jul 2010 21:10
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A Food and Drug Administration panel voted Wednesday to recommend that GlaxoSmithKline PLC's (GSK) diabetes drug, Avandia, remain on the market despite concerns the product could raise the risk of heart attacks. T
Read moreUPDATE: FDA Panel: Avandia Data Raise Significant Safety Concerns
14th Jul 2010 20:11
(Updates with additional information on panel votes starting in fifth paragraph; adds New York share price). By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A Food and Drug Administration panel said clinical data looking at GlaxoSmithKline PLC's (GSK) diabetes
Read moreFDA Panel: Avandia Data Raise 'Significant Safety' Concerns
14th Jul 2010 19:06
By Jennifer Corbett-Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A Food and Drug Administration panel said clinical data looking at GlaxoSmithKline PLC's (GSK) diabetes drug Avandia is strong enough to raise "significant safety" concerns about the product. The panel also said A
Read morePRESS RELEASE: S&P Withdraws Rtgs On SmithKline Beecham And SKB Holding Corp.
14th Jul 2010 17:02
The following is a press release from Standard & Poor's: FRANKFURT (Standard & Poor's) July 14, 2010--Standard & Poor's Ratings Services said today it withdrew its 'A+' long-term and 'A-1' short-term corporate credit ratings on U.K.-based SmithKline Beecham PLC, as well as its 'A+' long-term corpor
Read moreWednesday newspaper round-up: BP, BT, GlaxoSmithKline
14th Jul 2010 06:39
Democratic senators in the US are calling for an investigation into BP's business interests in Libya, accusing the British oil company of being part of a deal to free a convicted terrorist in return for oil licences. BP has faced a slew of Congressional investigations following its catastrophic oil
Read more2nd UPDATE: Calif Supreme Court Reinstates Suit Vs Drug Cos
13th Jul 2010 22:19
(Adds comment from Pfizer in the last paragraph.) By Peter Loftus Of DOW JONES NEWSWIRES The California Supreme Court has reinstated a lawsuit in which retail pharmacies accused Pfizer Inc. (PFE), AstraZeneca PLC (AZN, AZN.LN) and other major drug makers of conspiring to set prices at ar
Read more